One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction

American Heart Journal

Volumn 146, Issue 1, 2003, Pages 27-32

  Sinnaeve, Peter ^a   Alexander, John ^b   Belmans, Ann ^a   Bogaerts, Kris ^a   Langer, Anatoli ^c   Diaz, Rafaël ^d   Ardissino, Diego ^e   Vahanian, Alec ^f   Pehrsson, Kenneth ^g   Armstrong, Paul ^h   Van De Werf, Frans ^a,i  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Instituto Cardiovascular de Rosario   (Argentina)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f BICHAT HOSPITAL   (France)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH STATUS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 0037823123     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00117-0     Document Type: Article

References (9)

1. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-22.
2. Van de Werf FJ, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253-61.
3. Califf RM, White HD, Van de Werf FJ, et al, GUSTO-I Investigators. One-year results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.
4. Topol EJ, Ohman EM, Armstrong PW, et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III trial. Circulation 2000;102:1761-5.
5. Baigent C, Collins R, Appleby P, et al, The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998;316:1337-43.
6. Franzosi MG, Santoro E, De Vita C, et al, The GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto-1 study. Circulation 1998;98:2659-65.
7. Intravenous NPA for the Treatment of Infarcting Myocardium Early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-13.
8. Lesaffre E, Bluhmki E, Wang-Clow F, et al. The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. Eur Heart J 2001;22:898-902.
9. Siegel JP. Equivalence and noninferiority trials. Am Heart J 2000;139:S166-70.